Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

AstraZeneca’s tezepelumab and dapagliflozin accepted for use in Scotland

1
SHARES

The Scottish Medicines Consortium (SMC)’s acceptance means eligible patients across the UK can now benefit from AstraZeneca’s Tezspire (tezepelumab) for severe asthma and Forxiga (dapagliflozin) for chronic heart failure.

AstraZeneca’s tezepelumab and dapagliflozin accepted for use in Scotland by SMC

Credit: Alexanderstock23 / Shutterstock.com

Two of AstraZeneca’s key medicines have been recommended for use within NHS Scotland by the Scottish Medicines Consortium (SMC).

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Tom Keith-Roach, President of AstraZeneca UK announced: “We are pleased that the SMC has now accepted Forxiga (dapagliflozin) for use in patients with chronic heart failure with preserved or mildly reduced ejection fraction and Tezspire (tezepelumab) has been accepted for restricted use in severe asthma within NHS Scotland.”

First-in-class medicine tezepelumab now has the widest patient access for any severe asthma biologic in Scotland. The SMC has recommended the biologic as an add-on maintenance treatment for patients over 12 years, with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

The SMC’s acceptance is based on data from PATHFINDER clinical trial programme, including the NAVIGATOR Phase III trial, which showed a 56 percent reduction in the annualised asthma exacerbation rate (AAER) for tezepelumab versus placebo.

Pre-filled asthma pen approved for self-administration in EU

AstraZeneca’s chronic heart failure medicine

Dapagliflozin’s acceptance is based on the DELIVER Phase III trial, which showed that dapagliflozin was more effective than placebo in patients with HF with LVEF >40. It reduced the risk of a primary composite outcome of either worsening heart failure which was defined as either an unplanned hospitalisation for heart failure or an urgent visit for heart failure; or cardiovascular death.

AstraZeneca’s dapagliflozin has been accepted for symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) >40 percent. As it is already accepted for use in Scotland as a treatment option for heart failure patients with reduced ejection fraction (LVEF ≤40 percent), dapagliflozin can be used for chronic heart failure, regardless of ejection fraction.

First NICE-recommended treatment for chronic heart failure

Outcome of the SMC’s acceptance

AstraZeneca stated that approximately 4,000 people in Scotland may be eligible for tezepelumab to treat their severe asthma. More than 23,000 Scottish patients could be eligible for dapagliflozin treatment for symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) >40 percent.

Overall, SMC’s decisions will enable eligible patients across the UK to be treated with tezepelumab and dapagliflozin, which are already approved by the National Institute for Health and Care Excellence (NICE).

Share via
Share via